Moberg Pharma AB (publ) (MOB.ST)
SEK 7.95
(2.65%)
SEK 7.95
(2.65%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 634.73 Million SEK | 12.46% |
| 2022 | 564.42 Million SEK | 25.18% |
| 2021 | 450.88 Million SEK | -6.18% |
| 2020 | 480.57 Million SEK | 0.0% |
| 2018 | 1.25 Billion SEK | 2.32% |
| 2017 | 1.22 Billion SEK | -0.72% |
| 2016 | 1.23 Billion SEK | 210.02% |
| 2015 | 397.45 Million SEK | 10.49% |
| 2014 | 359.72 Million SEK | 32.44% |
| 2013 | 271.6 Million SEK | -3.26% |
| 2012 | 280.76 Million SEK | 203.68% |
| 2011 | 92.45 Million SEK | 646.64% |
| 2010 | 12.38 Million SEK | -64.92% |
| 2009 | 35.29 Million SEK | 56.28% |
| 2008 | 22.58 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 632.02 Million SEK | -0.43% |
| 2024 Q2 | 959.54 Million SEK | 51.82% |
| 2023 Q2 | 549.71 Million SEK | -0.29% |
| 2023 Q3 | 644.17 Million SEK | 17.18% |
| 2023 Q4 | 634.73 Million SEK | -1.47% |
| 2023 FY | 634.73 Million SEK | 12.46% |
| 2023 Q1 | 551.29 Million SEK | -2.33% |
| 2022 Q3 | 549.8 Million SEK | -1.06% |
| 2022 FY | 564.42 Million SEK | 25.18% |
| 2022 Q4 | 564.42 Million SEK | 2.66% |
| 2022 Q1 | 451.76 Million SEK | 0.19% |
| 2022 Q2 | 555.67 Million SEK | 23.0% |
| 2021 Q2 | 456.48 Million SEK | -1.45% |
| 2021 Q4 | 450.88 Million SEK | -0.58% |
| 2021 FY | 450.88 Million SEK | -6.18% |
| 2021 Q1 | 463.2 Million SEK | -3.44% |
| 2021 Q3 | 453.51 Million SEK | -0.65% |
| 2020 Q3 | 364.06 Million SEK | 0.0% |
| 2020 Q1 | 369.28 Million SEK | 0.75% |
| 2020 FY | 480.57 Million SEK | 0.0% |
| 2020 Q4 | 479.7 Million SEK | 31.77% |
| 2019 Q4 | 366.54 Million SEK | -70.26% |
| 2019 Q1 | 1.86 Billion SEK | 49.0% |
| 2019 Q2 | 1.2 Billion SEK | -35.12% |
| 2019 Q3 | 1.23 Billion SEK | 1.86% |
| 2018 Q2 | 1.26 Billion SEK | 3.8% |
| 2018 FY | 1.25 Billion SEK | 2.32% |
| 2018 Q4 | 1.25 Billion SEK | 0.37% |
| 2018 Q3 | 1.24 Billion SEK | -1.47% |
| 2018 Q1 | 1.21 Billion SEK | -0.32% |
| 2017 Q2 | 1.21 Billion SEK | -1.2% |
| 2017 Q1 | 1.22 Billion SEK | -0.45% |
| 2017 FY | 1.22 Billion SEK | -0.72% |
| 2017 Q4 | 1.22 Billion SEK | 2.39% |
| 2017 Q3 | 1.19 Billion SEK | -1.43% |
| 2016 Q2 | 726.09 Million SEK | 5.73% |
| 2016 Q3 | 835.92 Million SEK | 15.13% |
| 2016 Q4 | 1.23 Billion SEK | 47.4% |
| 2016 FY | 1.23 Billion SEK | 210.02% |
| 2016 Q1 | 686.73 Million SEK | 72.78% |
| 2015 Q4 | 397.45 Million SEK | -1.82% |
| 2015 Q3 | 404.82 Million SEK | -2.89% |
| 2015 FY | 397.45 Million SEK | 10.49% |
| 2015 Q1 | 405.17 Million SEK | 12.64% |
| 2015 Q2 | 416.87 Million SEK | 2.89% |
| 2014 Q4 | 359.72 Million SEK | 3.02% |
| 2014 Q3 | 349.17 Million SEK | -2.64% |
| 2014 Q1 | 281.02 Million SEK | 3.47% |
| 2014 Q2 | 358.63 Million SEK | 27.62% |
| 2014 FY | 359.72 Million SEK | 32.44% |
| 2013 Q1 | 265.94 Million SEK | -5.28% |
| 2013 Q3 | 275.8 Million SEK | 4.04% |
| 2013 FY | 271.6 Million SEK | -3.26% |
| 2013 Q4 | 271.6 Million SEK | -1.52% |
| 2013 Q2 | 265.1 Million SEK | -0.31% |
| 2012 Q4 | 280.76 Million SEK | 101.53% |
| 2012 FY | 280.76 Million SEK | 203.68% |
| 2012 Q3 | 139.31 Million SEK | 2.55% |
| 2012 Q2 | 135.85 Million SEK | 2.5% |
| 2012 Q1 | 132.54 Million SEK | 43.36% |
| 2011 FY | 92.45 Million SEK | 646.64% |
| 2011 Q2 | 77.52 Million SEK | 323.1% |
| 2011 Q4 | 92.45 Million SEK | 10.35% |
| 2011 Q3 | 83.78 Million SEK | 8.07% |
| 2011 Q1 | 18.32 Million SEK | 47.98% |
| 2010 FY | 12.38 Million SEK | -64.92% |
| 2010 Q4 | 12.38 Million SEK | 0.0% |
| 2009 FY | 35.29 Million SEK | 56.28% |
| 2008 FY | 22.58 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | -984.882% |
| AlzeCure Pharma AB (publ) | 32 Million SEK | -1883.476% |
| BioGaia AB (publ) | 2.33 Billion SEK | 72.796% |
| Enzymatica AB (publ) | 125.91 Million SEK | -404.112% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | -1745.956% |
| Gabather AB (publ) | 2.93 Million SEK | -21511.576% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | -768.069% |
| Nanexa AB (publ) | 132.25 Million SEK | -379.923% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | -598.498% |
| ODI Pharma AB | 12.27 Million SEK | -5070.935% |
| Orexo AB (publ) | 786.6 Million SEK | 19.307% |
| Probi AB (publ) | 1.55 Billion SEK | 59.06% |
| Swedencare AB (publ) | 9.52 Billion SEK | 93.334% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.143% |
| Toleranzia AB | 160.42 Million SEK | -295.652% |
| Vivesto AB | 355.87 Million SEK | -78.358% |